Literature DB >> 15976016

Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1.

Atsuyuki Kohara1, Takashi Toya, Seiji Tamura, Tomonari Watabiki, Yukinori Nagakura, Yoshitsugu Shitaka, Satoshi Hayashibe, Shigeki Kawabata, Masamichi Okada.   

Abstract

Metabotropic glutamate receptor type 1 (mGluR1) is thought to play important roles in the neurotransmission and pathogenesis of several neurological disorders. Here, we describe the radioligand binding properties and pharmacological effects of a newly synthesized, high-affinity, selective, and noncompetitive mGluR1 antagonist, 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198). YM-298198 inhibited glutamate-induced inositol phosphate production in mGluR1-NIH3T3 cells with an IC50 of 16 +/- 5.8 nM in a noncompetitive manner. Its radiolabeled form, [3H]YM-298198, bound to mGluR1-NIH3T3 cell membranes with a KD of 32 +/- 8.5 nM and a Bmax of 2297 +/- 291 fmol/mg protein. In ligand displacement experiments using rat cerebellum membrane, an existing noncompetitive mGluR1 antagonist 7-(hydroxyimino)cyclo-propa[b]chromen-1a-carboxylate ethyl ester (CPCCOEt) competitively displaced [3H]YM-298198 binding, although glutamate and other mGluR1 ligands acting on a glutamate site failed to inhibit [3H]YM-298198 binding, suggesting that YM-298198 binds to CPCCOEt (allosteric) binding sites but not to glutamate (agonist) binding sites. Specificity was demonstrated for mGluR1 over mGluR subtypes 2 to 7, ionotropic glutamate receptors, and other receptor, transporter, and ion channel targets. In in vivo experiments, orally administered YM-298198 showed a significant analgesic effect in streptozotocin-induced hyperalgesic mice at doses (30 mg/kg) that did not cause Rotarod performance impairment, indicating that it is also useful even for in vivo experiments. In conclusion, YM-298198 is a newly synthesized, high-affinity, selective, and noncompetitive antagonist of mGluR1 that will be a useful pharmacological tool due to its highly active properties in vitro and in vivo. Its radiolabeled form [3H]YM-298198 will also be a valuable tool for future investigation of the mGluR1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15976016     DOI: 10.1124/jpet.105.087171

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  29 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

2.  Two new non-competitive mGlu1 receptor antagonists are potent tools to unravel functions of this mGlu receptor subtype.

Authors:  T Knöpfel
Journal:  Br J Pharmacol       Date:  2007-05-14       Impact factor: 8.739

3.  Potent and specific action of the mGlu1 antagonists YM-298198 and JNJ16259685 on synaptic transmission in rat cerebellar slices.

Authors:  I Fukunaga; C H Yeo; A M Batchelor
Journal:  Br J Pharmacol       Date:  2007-05-14       Impact factor: 8.739

Review 4.  Metabotropic glutamate receptor ligands as potential therapeutics for addiction.

Authors:  M Foster Olive
Journal:  Curr Drug Abuse Rev       Date:  2009-01

5.  Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation.

Authors:  Karen J Gregory; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2015-03-25       Impact factor: 4.436

6.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 7.  Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.

Authors:  Shen Yin; Colleen M Niswender
Journal:  Cell Signal       Date:  2014-05-02       Impact factor: 4.315

Review 8.  Metabotropic glutamate receptors: physiology, pharmacology, and disease.

Authors:  Colleen M Niswender; P Jeffrey Conn
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

9.  Novel mGluR- and CB1R-independent suppression of GABA release caused by a contaminant of the group I metabotropic glutamate receptor agonist, DHPG.

Authors:  Carlos A Lafourcade; Longhua Zhang; Bradley E Alger
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

10.  Visual responses in mice lacking critical components of all known retinal phototransduction cascades.

Authors:  Annette E Allen; Morven A Cameron; Timothy M Brown; Anthony A Vugler; Robert J Lucas
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.